Summary of Bill S 2128

Bill Number: S 2128

Title: Relates to requiring certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

Status: Reported and Committed to Finance

Introduced: January 15, 2025

Classification: Bill

Purpose and Intent

Bill S 2128 aims to enhance transparency and affordability in prescription drug pricing by mandating that health insurance issuers certify that a significant portion of prescription drug rebates is passed on to patients at the point of sale. This legislation seeks to alleviate the financial burden on patients by ensuring they benefit directly from rebates that are typically negotiated between insurers and pharmaceutical companies.

Key Provisions

• Certification Requirement: Health insurance issuers must certify that at least 50% of the rebates received from pharmaceutical manufacturers for prescription drugs are provided to patients at the point of sale.

• Point of Sale Impact: The bill emphasizes that these rebates should reduce the out-of-pocket costs for patients when they purchase prescription medications, making them more affordable.

• Reporting Obligations: Issuers may be required to report on the amount of rebates provided to patients, ensuring compliance and accountability.

Who Would Be Affected

• Patients: Individuals purchasing prescription medications would benefit from reduced costs at the pharmacy counter, making medications more accessible.

• Health Insurance Issuers: Insurance companies will need to adjust their rebate management processes to comply with the new certification requirements.

• Pharmaceutical Manufacturers: Drug manufacturers may need to reconsider their pricing strategies and rebate structures in light of this legislation.

Procedural Aspects

• Legislative Timeline:

  • Introduced: January 15, 2025
  • Referred to Insurance Committee: January 15, 2025
  • Reported and Committed to Finance: March 24, 2025

• Sponsorship: The bill is primarily sponsored by Senator Robert Jackson, indicating legislative support for the initiative.

Related Legislation

• S 6489, S 2006, S 2393: These prior-session bills may have similar objectives or provisions related to prescription drug pricing and rebates.
• A 7142: This is a companion bill in the Assembly, suggesting a parallel effort to address the same issues in the lower chamber.

Conclusion

Bill S 2128 represents a significant step towards improving the affordability of prescription drugs for patients by ensuring that a majority of rebates are passed on at the point of sale. If enacted, it could lead to more transparent pricing practices and potentially lower out-of-pocket expenses for individuals relying on prescription medications.